InforCapital

Biotech Investors in Asia

4 investors found

Browse 4 Biotech Investors in Asia. Discover top investors, their portfolios, AUM, and investment focus on InforCapital.

aMoon

aMoon

InvestorIsrael1.0B AUM

Founded in 2016 and headquartered in Ra’anana, Israel, aMoon is a leading venture capital firm dedicated to transforming healthcare through groundbreaking science and technology. The firm was established by visionary entrepreneurs—including Marius Nacht (co-founder of Check Point Software) and Dr. Yair Schindel—and immediately set out to back moonshot innovations across digital health, life sciences, and medtech. aMoon operates globally, with a strategic presence in key innovation hubs. With a multidisciplinary team exceeding 50 scientists, physicians, and investment specialists, aMoon invests across the full company lifecycle through its fund platforms: aMoon Velocity (early-stage), aMoon Growth (mid-to-late-stage), and public equity strategies. Their strength lies in bridging early-stage scientific breakthroughs with global commercialization pathways, backed by deep domain expertise and global networks. Over the years, aMoon has built a strong track record—having made over 70 investments across healthcare and biotech, including recent deals in 2025, and backed notable exits like DayTwo and Omada’s IPO. Assets under management are estimated at over $1 billion, with some sources placing it between $750 million and $1.3 billion.

Kleiner Perkins

Kleiner Perkins

InvestorChina10.8B AUM

Kleiner Perkins, founded in 1972 by Eugene Kleiner and Tom Perkins, is a renowned venture capital firm based in Menlo Park, California. With a legacy of backing pioneering companies like Amazon, Google, and Genentech, the firm has been instrumental in shaping the technology landscape. Over the decades, Kleiner Perkins has invested in over 900 ventures, focusing on early-stage and growth-stage companies that drive innovation across various sectors. The firm's investment strategy encompasses a broad range of industries, including technology, healthcare, life sciences, and sustainability. Kleiner Perkins is known for its hands-on approach, partnering closely with entrepreneurs to provide not only capital but also strategic guidance and operational support. This collaborative model has led to numerous successful exits, including IPOs and acquisitions, solidifying its reputation as a top-tier venture capital firm. With offices in Menlo Park, San Francisco, and Shanghai, Kleiner Perkins maintains a global presence to support its diverse portfolio. The firm's commitment to fostering groundbreaking ideas and its track record of successful investments continue to attract visionary founders seeking to make a significant impact in their respective industries.

Lilly Asia Ventures (LAV)

Lilly Asia Ventures (LAV)

InvestorChina4.5B AUM

Lilly Asia Ventures is a prominent venture capital firm that specializes in investing in innovative healthcare companies across Asia. Founded in 2008, the firm leverages its deep industry expertise and extensive network to identify and support high-potential startups and growth-stage companies in the life sciences sector. With a strong focus on biotechnology, pharmaceuticals, and medical devices, Lilly Asia Ventures aims to drive advancements in healthcare by providing not only capital but also strategic guidance to its portfolio companies. The firm is committed to fostering innovation and improving patient outcomes through its investments. Over the years, Lilly Asia Ventures has built a diverse portfolio of companies that are at the forefront of medical research and technology. The firm prides itself on its collaborative approach, working closely with entrepreneurs and management teams to help them achieve their vision and scale their businesses effectively. As of the latest updates, Lilly Asia Ventures manages approximately $4.5 billion in assets, reflecting its strong position in the venture capital landscape. The firm is headquartered in Shanghai, China, and has a dedicated team of professionals with extensive experience in both investment and healthcare.

TF Capital

TF Capital

InvestorChina1.0B AUM

TF Capital is a venture capital firm headquartered in Shanghai, China, specializing in early-stage investments in the life sciences sector. Founded in 2013, the firm targets category-defining companies in biotechnology, therapeutics, pharmaceuticals, and related fields, providing not only capital but also strategic support through its network of advisors, industrialists, and tech leaders, particularly in the Asia Pacific region. The firm emphasizes full value-chain support, from proprietary sourcing and partnerships with listed companies and clinical experts to facilitating license-out deals generating over $2B in upfronts from 18 transactions across 11 companies. With a portfolio exceeding 100 companies, 20 IPOs, and 94 investments documented, TF Capital has backed notable exits like Zai Lab and Structure Therapeutics, focusing on preclinical, clinical-stage, and growth opportunities in pharma R&D and biomedical technology. TF Capital manages three funds, including Shanghai Taiyi Venture Investment Fund LP, and maintains a global outlook while prioritizing China-based innovation. Its team combines deep domain expertise with active involvement in go-to-market strategies, capital partnerships, and market insights to accelerate portfolio scaling in dynamic regions.

You reached the end.

Understanding Biotech Investors in Asia

The biotech sector in Asia is experiencing robust growth, driven by innovation and increasing demand for healthcare solutions. Biotech investors play a critical role in fueling this growth by providing the necessary capital and expertise to bring cutting-edge technologies to market. This curated directory of investors focuses on those with a strategic interest in the Asian biotech landscape, highlighting their unique role and investment strategies.

Investment Strategies and Focus Areas

Strategic Investment Approaches

Biotech investors in Asia typically adopt a forward-thinking approach, aligning their investments with emerging biotech trends and technological advancements. They often look for opportunities that promise not only financial returns but also significant advancements in healthcare delivery and outcomes. Their strategies may involve early-stage investments in innovative startups, as well as later-stage funding rounds for more established companies seeking to expand their market presence.

Focus on Innovative Solutions

These investors tend to prioritize companies that demonstrate potential for breakthrough innovations in areas such as genomics, bioinformatics, and personalized medicine. The goal is to back ventures that could revolutionize current medical practices, offering more effective and efficient solutions to pressing health challenges. By targeting these high-impact areas, biotech investors aim to maximize both societal benefits and financial returns.

Geographic Presence and Market Impact

Regional Influence and Expansion

Asia's diverse and dynamic markets present unique opportunities and challenges for biotech investors. With a strong presence in key markets such as China, India, and Southeast Asia, these investors are well-positioned to leverage local expertise and networks. Their geographic focus often extends beyond national borders, seeking cross-border collaborations and partnerships that can enhance the value of their portfolio companies.

Implications for Local and Global Markets

The strategic involvement of biotech investors in Asia not only accelerates regional innovation but also impacts global biotech trends. By nurturing local talent and fostering competitive biotech ecosystems, these investors contribute to the global supply chain of biotech innovations. This creates a ripple effect, enhancing the sector's overall growth and sustainability.

Why Biotech Investors Matter to LPs and Deal Professionals

Value Creation and Risk Management

For limited partners (LPs) and deal professionals, understanding the strategies and objectives of biotech investors in Asia is crucial. These investors not only provide financial capital but also bring valuable industry insights and networks, which can significantly de-risk investments. Their expertise in navigating regulatory landscapes and market dynamics is a key asset for maximizing value creation.

Opportunities for Strategic Partnerships

Engaging with biotech investors offers LPs and deal professionals access to a network of innovative companies and potential strategic partners. This can facilitate co-investment opportunities and joint ventures, enhancing the strategic reach and impact of their investments. By aligning with investors who are deeply embedded in the biotech ecosystem, they can leverage shared resources and insights to achieve their investment objectives.

In conclusion, biotech investors in Asia are pivotal players in the regional and global biotech sectors. Their strategic focus on innovation and market expansion offers significant opportunities for LPs and deal professionals seeking to engage with this dynamic industry. By understanding their investment strategies and regional influence, stakeholders can effectively navigate the complex landscape of biotech investments in Asia.

Browse all investor directories →